Customized Honeycomb Activated Carbon Solutions Transform Pharmaceutical Industry Emission Control

2026-02-02 16:36:46

The pharmaceutical industry faces unique emission challenges due to the diversity of pollutants—including solvents, APIs (Active Pharmaceutical Ingredients), and reaction byproducts—that require precise adsorption solutions. Honeycomb Activated Carbon manufacturers are now offering fully customized products tailored to the specific pollutant profiles of pharmaceutical processes, from API synthesis to formulation and packaging. A leading pharmaceutical company in Shanghai implemented a customized honeycomb activated carbon system designed to target acetone, methanol, and dimethylformamide (DMF)—common solvents in drug manufacturing. The solution featured a dual-layer design: a first layer with macro-pores (20–50 nm) to capture larger organic molecules and a second layer with micro-pores (-molecule solvents, achieving a combined removal rate of 99.6%. The carbon was also treated with amine groups to enhance adsorption of polar compounds like DMF, which are typically difficult to remove with conventional activated carbon. Additionally, the product was engineered to withstand the high-temperature exhaust streams (up to 120℃) from drying processes, with thermal stability tested up to 200℃ without significant performance degradation. The customized system reduced the company’s solvent emissions to below 10 mg/m³, well below China’s GB 37822-2019 standard of 80 mg/m³, and extended replacement cycles from 1.5 months to 6 months, cutting maintenance costs by 60%. For pharmaceutical plants operating under strict GMP (Good Manufacturing Practices) and environmental regulations, customized honeycomb activated carbon offers a compliant, efficient, and cost-effective solution that adapts to the unique demands of drug production processes, including batch-to-batch variations in pollutant composition.